Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Orexo AB ( (SE:ORX) ) has provided an announcement.
Orexo AB has appointed Friedrich von Bohlen as the new chairman of the board, succeeding James Noble. With over 25 years of experience in the biotech industry, von Bohlen brings a wealth of expertise to Orexo, which is poised for an exciting future centered around its AmorphOX® technology platform. The transition marks a strategic step for Orexo, aiming to create sustainable value for shareholders, patients, and partners, while acknowledging Noble’s contributions to the company’s financial stability and strategic development.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with 30 years of experience in developing improved pharmaceuticals using proprietary formulation technologies to address significant medical needs. The company provides innovative treatment solutions for opioid use disorder in the US and develops products for other therapeutic areas globally with leading partners. Orexo is listed on Nasdaq Stockholm and available as ADRs on the OTCQX market in the US.
Average Trading Volume: 14,966
Current Market Cap: SEK514.4M
See more data about ORX stock on TipRanks’ Stock Analysis page.